Mast Therapeutics Inc (MSTX)

8.76
8.63 6,587.02
NASDAQ : Health Care
Prev Close 0.13
Open 7.50
Day Low/High 7.50 / 9.90
52 Wk Low/High 0.07 / 0.71
Volume 73.19K
Avg Volume 5.10M
Exchange NASDAQ
Shares Outstanding 254.75M
Market Cap 33.12M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara

Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara

Over 95% of Votes Cast to Date are in Favor of the Merger, but More Votes Are Necessary to Achieve Quorum and Approval of All Required Proposals

Mast Reminds Stockholders To Vote For The Proposed Merger With Savara

Mast Reminds Stockholders To Vote For The Proposed Merger With Savara

-- Of the Votes Received to Date, More than 90% Are Voting in Favor of the Merger

Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market

Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market

Special Meeting of Mast Therapeutics Stockholders to Be Held on April 21, 2017

Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara

Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara

Special Meeting To Be Held on April 21, 2017

Mast Therapeutics And Savara Sign Merger Agreement

Mast Therapeutics And Savara Sign Merger Agreement

Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

How to Trade These Most Active Stocks -- LifeLock, Tyson Foods and More

How to Trade These Most Active Stocks -- LifeLock, Tyson Foods and More

Here's a technical look on how to trade some of the most active stocks on the market right now.

Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call

Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call

Call Scheduled Tuesday, November 8, 2016 at 4:30pm ET / 1:30pm PT

Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001

Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001

Agreement Covers Ongoing and Future Clinical Studies of AIR001

5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid

5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

Conference call scheduled for September 21, 2016 at 8:00am ET

Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care

Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care

Sickle Cell Disease Coalition launches a call to action on neglected disease

MSTX April 2017 Options Begin Trading

MSTX April 2017 Options Begin Trading

Investors in Mast Therapeutics, Inc saw new options become available today, for the April 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health

Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health

Grant will support evaluation of vepoloxamer as an adjuvant agent to thrombolytic therapy for the treatment of acute stroke

Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network

Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network

Study conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health